Sinotherapeutics Inc. A (688247) - Total Liabilities
Based on the latest financial reports, Sinotherapeutics Inc. A (688247) has total liabilities worth CN¥142.10 Million CNY (≈ $20.79 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Sinotherapeutics Inc. A to assess how effectively this company generates cash.
Sinotherapeutics Inc. A - Total Liabilities Trend (2020–2024)
This chart illustrates how Sinotherapeutics Inc. A's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Sinotherapeutics Inc. A to evaluate the company's liquid asset resilience ratio.
Sinotherapeutics Inc. A Competitors by Total Liabilities
The table below lists competitors of Sinotherapeutics Inc. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Warteck Invest Ltd
SW:WARN
|
Switzerland | CHF554.35 Million |
|
Betterware de México, S.A.P.I. de C.V.
NYSE:BWMX
|
USA | $8.81 Billion |
|
Chongqing Yukaifa Co Ltd
SHE:000514
|
China | CN¥3.18 Billion |
|
Kim Loong Resources Bhd
KLSE:5027
|
Malaysia | RM414.07 Million |
|
RaySearch Laboratories AB (publ)
ST:RAY-B
|
Sweden | Skr1.02 Billion |
|
Shandong Lubei Chemical Co Ltd
SHG:600727
|
China | CN¥5.23 Billion |
|
Core Laboratories NV
NYSE:CLB
|
USA | $317.19 Million |
|
Epigral Ltd.
NSE:EPIGRAL
|
India | Rs11.35 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Sinotherapeutics Inc. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sinotherapeutics Inc. A market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinotherapeutics Inc. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinotherapeutics Inc. A (2020–2024)
The table below shows the annual total liabilities of Sinotherapeutics Inc. A from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥180.30 Million ≈ $26.38 Million |
+19.12% |
| 2023-12-31 | CN¥151.36 Million ≈ $22.15 Million |
-2.38% |
| 2022-12-31 | CN¥155.05 Million ≈ $22.69 Million |
-3.47% |
| 2021-12-31 | CN¥160.62 Million ≈ $23.50 Million |
-11.14% |
| 2020-12-31 | CN¥180.76 Million ≈ $26.45 Million |
-- |
About Sinotherapeutics Inc. A
Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extende… Read more